<?xml version="1.0" encoding="UTF-8"?>
<ref id="R37">
 <label>37.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>van Schaik</surname>
    <given-names>IN</given-names>
   </name>, 
   <name name-style="western">
    <surname>Bril</surname>
    <given-names>V</given-names>
   </name>, 
   <name name-style="western">
    <surname>van Geloven</surname>
    <given-names>N</given-names>
   </name>, 
   <etal>et al</etal>
  </person-group>; 
  <collab>For the PATH Study Group</collab>. 
  <article-title>Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial</article-title>. 
  <source>Lancet Neurol</source>
  <year>2017</year>;
  <volume>17</volume>:
  <fpage>35</fpage>â€“
  <lpage>46</lpage>.
  <pub-id pub-id-type="pmid">29122523</pub-id>
 </mixed-citation>
</ref>
